We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

15% more funds holding

Funds holding: 102 → 117 (+15)

3.77% more ownership

Funds ownership: 48.64% → 52.41% (+3.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $140M → $125M (-$14.9M)

Holders
117
Holders Change
+15
Holders Change %
+14.71%
% of All Funds
2.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
40
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BC
Broadwood Capital
New York
+$6.72M
2
Axa
Axa
France
+$5.74M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.02M
4
Deutsche Bank
Deutsche Bank
Germany
+$1.53M
5
AG
Artal Group
Luxembourg
+$686K

Top Sellers

1
FM
Family Management
New York
-$374K
2
NFA
Nationwide Fund Advisors
Ohio
-$237K
3
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$164K
4
DWM
Destination Wealth Management
California
-$162K
5
Group One Trading
Group One Trading
Illinois
-$62.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
101
Bank of Montreal
Ontario, Canada
$7K +$299 +137 +4%
FDCDDQ
102
Federation des caisses Desjardins du Quebec
Quebec, Canada
$6.45K – – –
SWP
103
Stratos Wealth Partners
Ohio
$5K +$6.24K +2,858 New
Group One Trading
104
Group One Trading
Illinois
$4K -$62.6K -28,689 -92%
RFA
105
Reilly Financial Advisors
California
$4K – – –
CHP
106
Cable Hill Partners
Oregon
$3K -$4.99K -2,286 -67%
TWA
107
TCI Wealth Advisors
Arizona
$3K – – –
PCM
108
Poehling Capital Management
Wisconsin
$2K +$2.5K +1,143 New
SPIA
109
Steward Partners Investment Advisory
New York
$2K +$2.5K +1,143 New
VIA
110
Vantage Investment Advisors
Pennsylvania
$1K – – –
NFA
111
Nationwide Fund Advisors
Ohio
– -$237K -95,513 Closed
MLICM
112
Metropolitan Life Insurance Company (MetLife)
New York
– -$164K -65,827 Closed
CFA
113
Carroll Financial Associates
North Carolina
– -$47K -19,431 Closed
BA
114
BKS Advisors
Michigan
– -$28K -11,430 Closed
Royal Bank of Canada
115
Royal Bank of Canada
Ontario, Canada
– -$23.2K -10,644 -98%
Fifth Third Bancorp
116
Fifth Third Bancorp
Ohio
– -$12K -4,801 Closed
PCM
117
Prelude Capital Management
New York
– -$10K -4,115 Closed
RFC
118
Regions Financial Corp
Alabama
– +$124 +57 New
MAM
119
Meeder Asset Management
Ohio
– +$354 +162 New
1 2 3 4
5

LCTX Hedge Fund Activity: Q4 2017 in Review

117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2017, worth a combined $125M — down 11% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LCTX positions and 7 closed out — a net gain of 16 holders — while 40 added to existing stakes and 18 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $6.72M. The largest seller was Family Management, cutting an estimated $374K.

  • 117 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2017, up from 102 in Q3 2017.
  • Funds reported $125M of Lineage Cell Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 23 funds opened new Lineage Cell Therapeutics positions in Q4 2017 and 7 closed out, a net change of +16 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2017 was Broadwood Capital, an estimated $6.72M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2017 was Family Management, an estimated $374K sold.

Based on aggregated 13F filings for Q4 2017.